April 15, 2019Open Access

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

In the largest cfDNA study in previously untreated mNSCLC, a validated comprehensive cfDNA test identifies guideline-recommended biomarkers at a rate at least as high as SOC tissue genotyping, with high tissue concordance, more rapidly and completely than tissue-based genotyping.See related commentary by Meador and Oxnard, p. 4583.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Natasha B. Leighl

Ray D. Page

Victoria M. Raymond

Journals

Clinical Cancer Research

Actions

Institutions

The University of Texas MD Anderson Cancer Center

Princess Margaret Cancer Centre

City of Hope

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider